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Cancer stem cells (CSCs) of head and neck squamous cell carcinoma (HNSCC) are defined by 
high self-renewal and drug refractory potential. Involvement of Wnt/β-catenin signaling has been 
implicated in rapidly cycling cells such as CSCs, and inhibition of the Wnt/β-catenin pathway is 
a novel approach to target CSCs from HNSCC. In this study, we found that an antagonist of 
FrzB/Wnt, the secreted frizzled-related protein 4 (sFRP4), inhibited the growth of CSCs from 
two HNSCC cell lines, Hep2 and KB. We enriched the CD44+ CSC population, and grew them 
in spheroid cultures. sFRP4 decreased the proliferation and increased the sensitivity of spheroids 
to commonly used drug in HNSCC, namely cisplatin. Self-renewal in sphere formation assays 
decreased upon sFRP4 treatment, and the effect was reverted by the addition of Wnt3a. sFRP4 
treatment of spheroids also decreased β-catenin, confirming its action through the Wnt/β-catenin 
signaling pathway. Quantitative PCR demonstrated a clear decrease of the stemness markers 
CD44 and ALDH, and an increase in CD24 and drug resistance markers ABCG2 and ABCC4. 
Furthermore, we found that after sFRP4 treatment, there was a reversal in the expression of 
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epithelial to mesenchymal (EMT) markers with the restoration of the epithelial marker E-
cadherin, and depletion of EMT-specific markers twist, snail, and N-cadherin. This is the first 
report demonstrating that the naturally occurring Wnt inhibitor, sFRP4, can be a potential drug to 
destroy CSC-enriched spheroids from HNSCC. The repression of EMT and the decrease in 
stemness profile further strengthen the use of sFRP4 as a potent therapeutic against CSCs. 
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1.1 INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide 
(Van der Geer et al., 2010). Mortality from HNSCC is high because of distant metastases and the 
emergence of therapy-resistant tumors. Prognosis of HNSCC is determined by the degree of 
lymphatic invasion and metastasis at diagnosis (Parkin et al., 2005). The standard of care for 
patients with HNSCC includes primarily platinum-based chemotherapeutic drugs, surgery, and 
radiotherapy (Forastiere et al., 2001). Despite this, the 5-year survival rate for these patients has 
still been in the range of 50–60% for the last 3 decades (Carvalho et al., 2005). 
 
Cancer stem cells (CSCs), a small population of cells in most tumors, support tumor growth 
through their ability to self-renew and differentiate into heterogeneous tumor tissue. CSCs are 
typically resistant to radiation therapy and standard cytotoxic agents, which results in their 
enrichment and in the consequent recurrence of refractory tumors. After initially being identified 
in leukemia (Bonnet and Dick, 1997), they have been found in many solid tumors. CSCs have 
been identified in human HNSCCs using markers such as CD133 and CD44, and by aldehyde 
dehydrogenase (ALDH) activity (Prince, 2007). The presence of CSCs in HNSCC has been 
reported in many studies and has been comprehensively reviewed by Minnelli and Gallo 
(Mannelli and Gallo, 2012). The HNSCC CSCs reside in perivascular niches in the invasive 
front, where endothelial cells contribute to their survival and function.  
 
Targeting key signaling pathways that are active in CSC self-renewal is one approach to cancer 
therapy. Abnormal activation of the Wnt/β-catenin signaling pathway has been described in a 
wide variety of human cancers and in CSCs, and has already been demonstrated in HNSCC (Lim 
et al., 2012). Wnt dysregulation has a role in inducing epithelial to mesenchymal transition 
(EMT) transcription factors Twist and Snail (Yang et al., 2006, Reya and Clevers, 2005, Song et 
al., 2010). CSCs from hepatic carcinoma cell lines exhibited enhanced chemoresistance to 
cisplatin, which was reversed by lentiviral microRNA knockdown of β-catenin (Yang et al., 
2008). Similar studies have demonstrated that the Wnt/β-catenin signaling pathway was also able 
to confer chemoresistance to 5- fluorouracil and doxorubicin (Noda et al., 2009, Flahaut et al., 
2009). Activation of the Wnt pathway, by the Wnt receptor frizzled-1, induced expression of the 
multiple drug resistance gene MDR1 and promoted resistance to doxorubicin in chemoresistant 
neuroblastoma cells (Flahaut et al., 2009). In ovarian CSCs, ABCG2 was shown to mediate 
cisplatin and paclitaxel resistance, which was reversed by β-catenin siRNA knockdown (Chau et 
al., 2012).  
 
In this study, we investigated the effect of the naturally occurring protein secreted frizzled-
related protein 4 (sFRP4), which is an inhibitor of Wnt signaling, on CSC-enriched spheroid 
cells from two HNSCC cell lines. We examined the ability of sFRP4 to chemosensitize spheroids 
to commonly used therapeutic drugs and studied CSC-specific properties such as self-renewal, 
the expression of CD44 positive cells, and the ability to form spheres in culture. To explore the 
underlying molecular mechanism of sFRP4, we examined the Wnt/ß-catenin signaling pathway, 
changes in the EMT profile with relation to sFRP4, and the expression of drug resistance 
markers.  We identified that sFRP4 enhanced the chemosensitivity of CSC-enriched cells by 
inducing apoptosis, reducing EMT, and decreasing stemness properties. Our findings are relevant 
in the context of designing drugs targeting CSCs, as sFRP4 is a natural Wnt antagonist acting 
only on cells having dysregulated Wnt/ß-catenin signaling. These studies identify sFRP4 as a key 
Wnt antagonist that can regulate CSC maintenance and chemoresistance, which can lead to better 
targeted modes of cancer therapy.  
 
1.2 MATERIALS AND METHODS 
1.2.1 CELL LINES 
The two cell lines Hep2 (laryngeal carcinoma) and KB (tongue carcinoma) used in this study 
were purchased from the National Center of Cell Sciences, Pune, India, and cultured and 
maintained in DMEM/F-12 and DMEM-LG (Gibco) (1:1) containing 1X GlutaMax (Life 
Technologies), 10% Fetal Bovine Serum (Hyclone), and 100U/mL PenStrep (Life 
Technologies). Normal non-tumorigenic mouse embryonic fibroblasts (MEFs), were isolated 
from mouse embryo day e10.5 and cultured the DMEM-KO medium containing 1X GlutaMax 
(Life Technologies), 10% Fetal Bovine Serum (Hyclone), and 100U/mL PenStrep (Life 
Technologies). Serum free medium (SFM) for sphere culture was performed in basal medium 
(DMEM/F-12 + DMEM-LG) with 100U/mL PenStrep, 2mM GlutaMAX, and containing 20 
ng/mL each of epidermal growth factor (EGF), basic fibroblast growth factor (bFGF; R&D 
Systems), and leukemia inhibitory factor (LIF; Chemicon). All cells were cultured at 37°C in a 
humid incubator with 5% CO2. CSC populations were enriched by plating a single cell 
suspension of Hep2 and KB cells at 5,000 cells per mL in SFM on non-adherent 6 well plates 
(BD Biosciences) as reported previously (Warrier et al., 2014).  The medium was replenished 
once in 2 days by centrifuging for 3 min at 450 × g at room temperature, aspirating the medium, 
and replacing it with fresh stem cell medium till the spheres were >120 μm in size, as observed 
using an inverted phase contrast microscope (Nikon Eclipse TE 2000-S, Japan). Spheres were 
then characterized for the expression of CSC markers CD44 and ALDH by flow cytometry and 
qPCR. After identifying for CSC enrichment of the spheres, spheroids were used for further 
analysis. 
 
1.2.2 PROLIFERATION ASSAYS 
MTT 
The TACS MTT assay kit (R&D Systems) was used according to the manufacturer’s protocol to 
measure cell metabolic viability.  
Hep2 and KB spheroids were cultured in non-adherent SFM conditions (10,000 cells/mL) in 96-
well plates. Drugs used were sFRP4 (250pg/ml), cisplatin (10mM), and doxorubicin (50ug/mL). 
The following treatment groups were examined: sFRP4- (S), cisplatin- (C), sFRP4 + cisplatin 
(S+C), doxorubicin- (D), and sFRP4 + doxorubicin (S+D) for a treatment time of 24h. After drug 
treatment, an MTT assay was performed and the plates were read at 595 nm using a Victor 3 
Multilabel Plate Reader (Perkin-Elmer). As the combination of S+C was the most effective, 
subsequent analysis was performed using C and S+C. 
 
BrdU ASSAY 
Hep2 and KB spheroid cultures were subjected to the following drug conditions: sFRP4- 
250pg/mL (S), cisplatin- 10mM (C), and a combination of sFRP4 and cisplatin (S+C). The same 
drug treatment was performed for the remainder of the experiments. Hep2 and KB spheres were 
treated with various drugs, and cell proliferation was measured using the BrdU Cell Proliferation 
Assay Kit (Cell Signalling Tech Inc) according to the manufacturer’s protocol. Plates were read 
at 450nm using a Victor 3 Multilabel Plate Reader.  
 
1.2.3 SECONDARY SPHERE FORMING ASSAY 
Primary spheres were obtained by plating 10,000 cells/mL, under SFM conditions, in ultra-low 
adherence, 6-well culture plates. On day 2, primary spheres were subjected to drug treatment as 
indicated. After treatment, the primary spheres from each condition were disrupted into single 
cell suspensions and were replated for secondary sphere formation under each condition. The 
secondary spheres were observed for morphology, and the total number of spheres were counted, 
together with the number of spheres of different sizes using a bright field phase contrast 
microscope (Nikon- Eclipse TE 2000-S), and photographs were taken using Qimaging- QICAM-
fast 1394.  
 
1.2.4 CASPASE ASSAY 
After treatment of Hep2-spheroids and KB-spheroids with the various drug treatments, the 
activity of apoptosis-inducing caspase-3 was assayed using the EnzChek DEVD-CHO Caspase3 
Assay Kit (Invitrogen), which provides a fluorescent substrate R110. Intensity of the 
fluorescence is correlated with an increase in caspase-3 activity, and the fluorescence intensity 
was measured using a Victor 3 Multilabel Plate Reader at 485/535 nm (Ex/Em). 
 
1.2.5 SEMI-QUANTITATIVE REVERSE TRANSCRIPTION-PCR: 
Total RNA was extracted from Hep2-spheroids and KB-spheroids after drug treatment using the 
RNeasy Plus Mini kit (Qiagen) according to the manufacturer’s instructions. Total RNA was 
reverse-transcribed using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, 
CA). RNA (1 μg) was mixed with 1 μL Oligo dT (50 μM) and 1 μL of dNTP (10mM), made up 
to 13 μL with DEPC treated water,  and heated at 65°C for 10 minutes, followed by incubation 
on ice. After primer hybridisation, 7 μL reaction volume containing 5X first strand buffer, RNase 
OUT (40U/μL), 0.1 M DTT, and Superscript III were added to the RNA and subjected to 
thermocycling (25°C, 5 min; 50°C, 60 min; 70°C, 15 min) in a Veriti 96 well thermal cycler 
(Applied Biosystems). Qualitative expression of markers for CSC, apoptosis, drug resistance, 
and EMT (primers from Sigma, sequence as indicated in Tables 1 and 2) were analyzed by PCR 
(95°C 30s; annealing temperature, 30s; 72°C 30s for 40 cycles) in a Veriti 96 well thermal 
cycler. Products were resolved in 1.5 % agarose gel electrophoresis and detected using ethidium 
bromide. Integrated density values (IDV) were calculated using Alpha manager. 
 
1.2.6 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION-PCR.  
The mRNA expression of different genes obtained qualitatively was further quantified using iQ 
SYBR Green Supermix (Bio-Rad, Hercules, CA) in a real time PCR system. cDNAs and gene-
specific primers were mixed with 2X iQ SYBR Green Supermix (Bio-Rad), and dispensed on a 
MicroAmp® Optical 8-Tube Strip. Fluorescence shift was observed using a 7500 Real-time PCR 
system (Applied Biosystems). Reaction parameters were 50°C for 2 minutes, 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. PCR products 
were verified by melting curves. The relative abundance of mRNAs was obtained using the 
comparative cycle threshold method and was normalized to the housekeeping control gene 
GAPDH, and ΔCT was calculated by subtracting the CT value of the GAPDH reference gene 
from that of each gene. Results were also expressed as fold changes (ΔΔCT) in the mRNA levels 
of a gene compared to the treated or untreated samples. 
 
1.2.7 WESTERN BLOTTING 
Protein expression levels of ß-catenin, the central component of canonical Wnt signaling, were 
determined by Western blotting. Equal amounts of cell lysate were resolved by SDS-PAGE, 
transferred to polyvinylidene difluoride membranes (Millipore), and detected with antibodies 
targeting either anti-human mouse ß-catenin mAbs at 1:500 dilution (R & D Systems, MN, 
USA), or anti-human mouse actin mAbs at 1:500 dilution (Millipore). Rabbit anti-mouse Horse 
Radish Peroxidase linked secondary antibodies (1:3000) were used to bind to the primary 
antibody. The blot was developed with enhanced chemiluminescence reagent (Pierce, IL) and 
images were captured using AlphaImager (CA, USA). 
 
1.2.8 STATISTICAL ANALYSIS  
Data represent mean and SE from experiments done in triplicate and were determined with a 




1.3.1 sFRP4 inhibits HNSCC spheroids at low dosage and increases the response with 
chemotherapeutics via the apoptotic pathway 
To investigate the effect of sFRP4 on CSC enriched cells, we used two HNSCC cell lines. The 
effect of sFRP4 on CSC-enriched cells from the KB and Hep2 cell lines was tested with MTT 
and BrdU assays. It was observed that sFRP4 inhibited proliferation and, in combination with 
commonly used oral cancer chemotherapeutics such as cisplatin and doxorubicin, inhibition was 
more pronounced. The combination of cisplatin and sFRP4 effectively reduced the viability to 
25% in both Hep2-spheroids and KB-spheroids (Fig 1a, b), and hence, cisplatin was used in the 
subsequent studies. The caspase-3/7 assay showed induction of apoptosis by the activation of 
caspase 3/7 enzyme and was maximal in the S+C treated cells (Fig 1c). 
 
1.3.2 Self-renewal and CSC specific markers of Hep2-spheroids and KB-sheroids reduced 
by sFRP4 
One of the strategies used for the enrichment of CSCs and for the analysis of self-renewal, a 
hallmark property of CSCs, is to study the formation of clonogenic spheres and secondary sphere 
formation. We have previously reported the formation of secondary spheres by the CSCs 
enriched from glioma cell lines (Warrier et al., 2012). We show that addition of sFRP4, and in 
combination with cisplatin, drastically disrupted the formation of secondary spheres (Fig 2a) and 
there was no clonogenic expansion. Expression of the CSC-specific marker CD44 was reduced 
markedly in sFRP4 treated and in sFRP-Cis treated Hep2-spheroids and KB-spheroids, as 
demonstrated by immunohistochemistry (Fig 2b). Flow cytometry showed a modest decrease in 
CD44 positive cells (Fig 2c).  
 
1.3.3 Inhibition by sFRP4 is through the Wnt/ß-catenin signaling pathway 
As sFRP4 is a known antagonist of the Wnt pathway, we used the Wnt agonist, Wnt3a, and the 
GSK-3ß inhibitor, lithium chloride, in our assay to see their effect on sFRP4-mediated inhibition. 
In sFRP4 treated cells, Wnt3a and LiCl increased proliferation of Hep2-spheroids and KB-
spheroids and reversed the inhibition produced by sFRP4 (Fig 3a). Non-tumorigenic fibroblastic 
cells, MEFs, however, showed no effect upon various drug treatments. Further confirmation that 
the mode of action of sFRP4 is through the Wnt/ß-catenin axis was provided by Western blotting 
of sFRP4 and cisplatin treated Hep2-spheroids. It was seen that, after sFRP4 and cisplatin 
treatment, there was a marked reduction of ß-catenin protein, suggesting that sFRP4 abolishes 
accumulation of ß-catenin via the Wnt/ß-catenin signaling pathway (Fig 3b). 
 
1.3.4 sFRP4 upregulates apoptotic genes and represses stemness genes 
We studied expression of genes such as Cyclin D1, a regulator of cell cycle progression, Bax, a 
key promoter of apoptosis, and p21, a cyclin dependant kinase inhibitor, in Hep2-spheroids and 
KB-spheroids by q-PCR following treatment with sFRP4 and cisplatin. We found that treatment 
with sFRP4 in combination with cisplatin, activated Bax and p21 gene expression but reduced 
the expression of Cyclin D1, proliferation markers Ki67 and MDM2, and inhibitor of apoptosis, 
xIAP (Fig 4,b). As the CSC enriched cells had high levels of CSC-associated genes such as 
CD44 and ALDH, we analyzed the expression of these genes under the various drug treatments. 
We found that all these genes were downregulated in sFRP4 and cisplatin treated spheroids 
derived from both Hep2 and KB cell lines (Fig 4a, b).  
 
1.3.5 sFRP4 downregulated EMT promoting genes and drug resistance genes 
Epithelial to mesenchymal transition (EMT), a typical trait of CSCs, is accompanied by a shift in 
cadherin expression from E-cadherin to N-cadherin. We found a reversal of EMT with the 
accumulation of E-cadherin and a reduction in N-cadherin levels in sFRP4, cisplatin, and 
combination treated Hep2-spheroids and KB-spheroids. In addition, we observed that the 
molecular markers implicated in EMT, such as twist and snail, were downregulated in spheroids 
treated with sFRP4 and cisplatin (Fig. 4a, b). The expression of the ABC genes ABCG2 and 
ABCC4, which are involved in drug efflux and are normally upregulated in CSCs, were also 
analyzed and we observed that their expression was reduced in sFRP4-cisplatin treated Hep2-
spheroids (Fig. 4 a, b). 
1.4 DISCUSSION 
Cancer stem cells have remained an elusive and ever changing population present within tumors. 
As their isolation from tumor tissue is a challenge, enrichment of CSCs from cell lines is an ideal 
alternative for the testing of novel drugs that can inhibit these highly refractory and 
chemoresistant populations. Due to their closeness to normal stem cells, CSCs rely on pathways 
that govern development, self-renewal, and cell fate. These pathways are largely regulated by 
three signaling programs; namely, the Wnt (Haegebarth and Clevers, 2009, Wang et al., 2010), 
Notch (Fan et al., 2010, Wang et al., 2010), and Hedgehog (HH) pathways (Dierks et al., 2008, 
Hofmann et al., 2009). Aberrant Wnt/ß-catenin signaling has been implicated in numerous 
malignancies attributed to the constitutive hyper-activation of the pathway. A level of regulation 
in normal cells that keeps ß-catenin levels in check is the presence of antagonists of the Wnt 
pathway, which either bind Wnt ligands or Wnt receptors, or both (Kawano and Kypta, 2003).  
 
The sFRPs are structurally related to the frizzled (Fz) receptors and are antagonists of Wnt 
signaling functioning by interacting with both Wnts and Fz receptors (You et al., 2004, Lee et 
al.,2004). It has been shown that sFRP4 is involved in the regulation of apoptosis, proliferation, 
tissue formation, and tumor growth (Guo et al., 1998, Lacher et al., 2003, Feng et al., 2006, 
Hewitt et al., 2006). In this study, we show that similar to our early report on glioma CSCs 
(Warrier, 2014), sFRP4 was effective in improving the chemoresponse of CSC-enriched 
spheroids from HNSCC cell lines to the commonly used chemotherapeutic cisplatin.  
 
As the sFRP4 mediated inhibition operates through the Wnt/ß-catenin signaling pathway, we 
could demonstrate that the inhibition by sFRP4 was rescued by the addition of a Wnt ligand such 
as Wnt3a. Inhibition by sFRP4 is relayed downstream by the activation of GSK3ß kinase and by 
the phosphorylation of ß-catenin. We could show that LiCl (an inhibitor of GSK3ß kinase), could 
also remove the inhibition brought about by sFRP4. Activation and accumulation of ß-catenin in 
the cytoplasm will result in the nuclear translocation of ß-catenin. In the nucleus, ß-catenin binds 
to the transcription factors of the T-cell factor- lymphocyte enhancing factor family, upregulating 
genes associated with proliferation and migration such as cycD1, c-myc, and cox2. Our 
observations of downregulation of the proliferation associated gene, cycD1, together with an 
increase in the Wnt-regulated apoptotic genes, Bax and p21, indicate the initiation of the 
apoptotic process by suppression of Wnt signaling.  
 
Wnt activity determines stemness and self-renewal of CSCs from colon cancers (Kaler et al., 
2009) and breast cancers (Lamb et al.,2013), and WNT pathway activation is significantly higher 
in breast CSCs, whereas normal stem-like cells have lower levels of WNT signaling (Klopocki et 
al., 2004). Our data clearly indicate that sFRP4 is able to reduce the sphere forming and self-
renewal ability of the CSC enriched HNSCCs. Furthermore, HNSCC-specific CSC markers such 
as CD44 and ALDH are downregulated by sFRP4 treatment. Pancreatic CSCs, identified by 
CD44+CD24- and ALDH expression, have been shown to be sensitized to TNF-related 
apoptosis-inducing ligand (TRAIL)-induced apoptosis by sulforaphane, which acts by 
dysregulating anti-apoptotic NF-B signaling (Kallifatidis et al., 2009). A similar mechanism 
may govern the dramatic reduction in self-renewal, clonogenicity, and CSC marker expression 
caused by sFRP4 treatment in conjunction with chemotherapeutic drugs in HNSCC spheroids. 
 
EMT is a reversible dedifferentiation process converting epithelial cancer cells to 
dedifferentiated cells with mesenchymal properties, and is characterized by the loss of epithelial 
features and the acquisition of mesenchymal traits (Eccles and Welch, 2007, Thiery et al., 2009). 
The EMT transcription factors ZEB1/2 have been shown to be overexpressed in CSC-like cells 
in HNSCC and are linked to decreased survival rates, increased sphere formation, CD44+ cells, 
tumor growth, and metastasis (Thiery, 2002). Loss of E-cadherin is the fundamental event in 
EMT. E-cadherin is a tumor invasion suppressor and is downregulated in most carcinomas, while 
N-cadherin, an invasion promoter, is frequently upregulated in the EMT switch.  Upon EMT 
conversion, epithelial cells lose cell-cell adhesion and cell polarity, and have decreased 
expression of  E-cadherin, and an increase in mesenchymal cell markers vimentin, fibronectin, 
N-cadherin, α smooth muscle actin (α-SMA), as well as increased activity of matrix 
metalloproteinases (MMPs) such as MMP-2, MMP-3, and MMP-9, which are associated with an 
invasive phenotype (Chu et al., 2013). The reversible downregulation of E-cadherin (encoded by 
CDH1) involves either hypermethylation of the CDH1 promoter or repression by EMT-inducing 
transcription factors (Thiery and Sleeman, 2006, Thiery et al., 2009). The loss of E-cadherin 
releases β-catenin into the cytosol and elicits activation of the canonical Wnt signaling pathway 
(Chu et al., 2013).  An increased expression of E-cadherin over N-cadherin, which we observed 
following sFRP4 treatment, indicates a reversal of EMT. This phenomenon is further 
corroborated in our study by the downregulation of Twist and Snail, which are transcriptional 
repressors of E-cadherin (Chu et al., 2013).  
 
ABC drug transporters are overexpressed in both normal stem cells and many CSCs as drug 
efflux pumps (Polyak and Weinberg 2009, Lou and Dean, 2007). Of the ABC transporters 
examined, we found a decrease in the expression of ABCG2 and ABCC4 in sFRP4 and drug 
treated spheroids. ABCG2 is an important member of ABC transporter family, and is one of the 
potential markers of CSCs that facilitate the mechanism of multidrug resistance (MDR), and is 
an important determinant of the CSC side population phenotype (Haraguchi et al., 2006, Lim et 
al., 2011). 
 
The CSC assay technique used in this study, which utilizes CSC enrichment in stringent low 
attachment, serum-free culture, is an effective platform for multiple drug screening. We have 
shown that sFRP4, an endogenously expressed Wnt antagonist, is able to inhibit CSC growth and 
render these cells more responsive to chemotherapeutics. sFRP4 has no inhibition in normal non-
cancerous cells because these cells have a low level of Wnt signaling. Hopefully, this study 
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Figure 1: Inhibition of HNSCC CSCs by sFRP4 and Cisplatin  
a) MTT proliferation assay of Hep2 and KB spheroids showed an inhibition with sFRP4- 
250pg/mL (S), doxorubicin- 50ug/mL (D),  cisplatin- 10mM  (C) , sFRP4 + doxorubicin (S+D), 
and sFRP4 + cisplatin (S+C). 
b) Percentage of live cells was determined by a BrdU assay, which demonstrated that S+C 
treated cells had maximal cell death. 
c) The caspase-3 assay showed that apoptotic cell death had occurred and was the highest in S+C 
treated cells. 
Results are the mean ± SD of three independent experiments performed in triplicates (* p value 
<0.05, ** p value <0.01, n=3). 
 
Figure 2: Analysis of CSC properties- sphere forming assay, immunohistochemistry, and 
CD markers analyses 
a) Self-renewal by secondary sphere forming assay shows that sFRP4 treatment (S) disrupted 
sphere formation, and combination treatment (S+C) showed a marked reduction. (U) is the 
untreated control. 
b) Immunohistochemistry of CSC specific marker CD44 of Hep2 and KB spheroids shows a 
similar pattern of reduction of CD44 expression. Nuclei have been stained with DAPI. 
c) Flow cytometry of KB CSCs shows a decrease in CD44 expression. 
 
Figure 3: Analysis of inhibition of sFRP4 effect by Wnt/β-catenin pathway regulators 
a) Wnt agonist, Wnt3a, and GSK3-ß inhibitor lithium chloride (LiCl), increased proliferation of 
sFRP4 treated Hep2 and KB cells whereas all the drug treatment had no significant effect on 
non-tumorigenic mouse embryonic fibroblasts (MEF). 
Results are the mean ± SD of two independent experiments performed in triplicates (* p 
value <0.05, ** p value <0.01, n=3). 
 
b) Western blot analysis of ß-catenin in Hep2 and KB spheroids shows that ß-catenin 




Figure 4: Expression study of apoptotic genes, stemness genes, EMT and drug-resistant 
markers by semi-quantitative and quantitative RT-PCR 
 
CyclinD1, Xiap, MDM2 and Ki67 levels, as represented by semi qPCR (a) quantified by qPCR 
(b), were reduced in S, C, and S+C treated Hep2 and KB spheroids, and the expression of 
apoptosis-inducing genes Bax and p21 increased upon drug treatment. CSC-associated genes 
CD44 and ALDH decreased, but CD24, a negative CSC marker, was shown to increase in both 
Hep2 and KB-CSCs (a, b1, b2). EMT-specific markers Twist and Snail decreased. Mesenchymal 
to epithelial switch was demonstrated by the decrease in N-cadherin and increase in E-cadherin 
(a, b1, b2). Decreased levels of drug resistance markers, ABCG2 and ABCC4 (a, b1, b2) were 
seen in the drug treated spheroids. A similar trend was observed in both Hep2 and KB-spheroids. 
(U) represents the untreated control. Results are the mean ± SD of two independent experiments 


















Table 1- : Primer sequences for apoptosis and stemness related genes 
Genes Primers Base 
pair 
Annealing 
temperature  ºC 
GAPDH F- 5’ CAGAACATCATCCCTGCATCCACT 3’ 





Cyclin D1 F- 5’ AACTACCTGGACCGCTTCCT 3’ 
R- 5’ CCACTTGAGCTTGTTCACCA 3’ 
187 61 
xIAP F- 5’GGGGTTCAGTTTCAAGGACA3’                    
R- 5’ CGCCTTAGCTGCTCTTCAGT3’ 
183 56 
Mdm-2 
F- 5’ TTACCCAGGCTGGAGTGCAG 3' 
R- 5' GAGAATGGTGCGAACCCG 3' 
92 
60 
Ki67 F- 5 CTGCTTTGGGGACTTGACG 3’ 
R- 5 GTCGACCCCGCTCCTTTT 3’ 
201 62 
Bax F- 5’ GCTGGACATTGGACTTCCTC 3’ 
R- 5’ TCAGCCCATCTTCTTCCAGA 3’ 
247 61 
p21 F- 5’GAGGCCGGGATGAGTTGGGAGGAG 3’ 
R- 5’ CAGCCGGCGTTTGGAGTGGTAGAA 3’ 
220 63 
CD44 F- 5’ CATCTACCCCAGCAACCCTA 3’ 




ALDH  F- 5’AAAGTCAAAGGCTTCCTGCCC 3’ 




F-  5’ AACTAATGCCACCACCAAGG 3’ 
R- 5’ CCTGTTTTTCCTTGCCACAT 3’ 
188 55 
 
Table 2- : Primer sequences for EMT and drug resistance associated genes 
 





Twist F- 5’ CAGCGCACCCAGTCGCTGAA 3’ 
R- 5’ CGCCCCACGCCCTGTTTCTT  3’ 
438 53 
Snail F- 5′ GAGGCGGTGGCAGACTAG  3′ 
R- 5′ GACACATCGGTCAGACCAG  3′ 
159 60 
N-cadherin F- 5′CTCCTATGAGTGGAACAGGAACG 3′ 
R- 5′TTGGATCAATGTCATAATCAAGTGCTGTA 3′ 
121 63 
E-cadherin   F- 5′ATTCTGATTCTGCTGCTCTTG 3′ 
R- 5′ AGTAGTCATAGTCCTGGTCTT 3′ 
400 60 
ABCG2 F- 5’ CACAGGTGGAGGCAAATCTT 3’  




F- 5’ CCATCTGTGCCATGTTTGTC 3’  
R- 5’ AGGGCTGAGATGAGGGAACT 3’ 
403 60 
